Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine plus infliximab versus infliximab alone for hospitalized adults with COVID-19
IRCT20200325046854N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of colchicine and infliximab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Clinical symptom evaluation, Chest CT scan changes and 2 more. Started Mar 2021; status: completed.
02
Drugs
colchicineinfliximab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200325046854N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200325046854N2.